Alector lays off 17% of staff after phase 2 Alzheimer's drug fail
2 days ago · Alector removed AL003 from its pipeline but continued work with AbbVie on AL002. Across both AL002 and AL003, the deal was worth up to $985.6 million in option exercise and milestone payments ...
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II ...
2 days ago · Alector is kicking off a resource realignment effort that will include a workforce reduction. The biotech expects its current cash position to last it through 2026. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals ...
Alector turns to layoffs as Alzheimer’s drug fails
2 days ago · Alector recorded a net loss of $42 million during the third quarter. AL002 is an antibody drug designed to activate a protein found on the surface of certain cells made in the bone marrow. Studies suggests this “TREM2” protein performs a variety of important functions , with one being the promotion of immune cells that reside in the brain.
Alector stock drops after Alzheimer’s drug fails in Phase II trial
2 days ago · Latest News. Stock Market. Originals. The Morning Brief. Premium News. Economics. Housing. Earnings. Tech. ... AL002 is a monoclonal antibody that Alector was developing to slow down Alzheimer’s ...
Alector Therapeutics’ novel Alzheimer’s strategy fails in ... - STAT
2 days ago · Alector Therapeutics said Monday that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what had been one of the leading dark horse approaches to treating the ...
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid …
2 days ago · As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide a runway through 2026.
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in ...
3 days ago · SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial
3 days ago · Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected]. 1AB (media) Dan Budwick 973-271-6085 [email protected]. Argot Partners (investors) Laura Perry 212-600-1902
Alector Presents Results from First-in-Human Phase 1 Study of …
Nov 30, 2022 · Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune …
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 …
Feb 8, 2024 · Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient ...